Non-small cell lung cancer
Executive Summary
FDA's Oncologic Drugs Advisory Committee will consider appropriate endpoints for non-small cell lung cancer clinical trials at a Dec. 16 meeting, as part of the agency's ongoing 1project on cancer endpoints. The meeting will follow up on an April 15 workshop, where FDA noted most oncology approvals are not based on survival endpoints (2"The Pink Sheet" April 21, 2003, p. 25). ODAC will also discuss "general issues on [cancer] clinical trial design and endpoints." The meeting will be held at the Holiday Inn in Bethesda, Md. beginning at 8 a.m. [To watch a 3webcast of this meeting, go to FDAAdvisoryCommittee.com]....
You may also be interested in...
“Underpowered” Cancer Trials Are Becoming “Major Problem” – FDA’s Pazdur
Cancer drug trials that are statistically "underpowered" because of their small size are becoming a "major problem," FDA Oncologic Drug Products Division Director Richard Pazdur, MD, told a joint American Society of Clinical Oncology/FDA workshop April 15 in Alexandria, Va
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.